Anne G Ording1, Erzsébet Horváth-Puhó1, Katalin Veres1, M Maria Glymour2, Mikael Rørth1, Henrik T Sørensen1, Victor W Henderson1,3,4. 1. Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark. 2. Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA. 3. Department of Epidemiology & Population Health, Stanford University, Stanford, California. 4. Department of Neurology & Neurological Sciences, Stanford University, Stanford, California.
Abstract
INTRODUCTION: Small observational studies with short-term follow-up suggest that cancer patients are at reduced risk of Alzheimer's disease (AD) compared to the general population. METHODS: A nationwide cohort study using Danish population-based health registries (1980-2013) with cancer patients (n = 949,309) to identify incident diagnoses of AD. We computed absolute reductions in risk attributed to cancer and standardized incidence rate ratios (SIRs) accounting for survival time, comparing the observed to expected number of AD cases. RESULTS: During up to 34 years of follow-up of cancer survivors, the attributable risk reduction was 1.3 per 10,000 person-years, SIR = 0.94 (95% confidence interval 0.92-0.96). SIRs were similar after stratification by sex, age, and cancer stage, and approached that of the general population for those surviving >10 years. DISCUSSION: Inverse associations between cancer and AD were small and diminished over time. Incidence rates in cancer survivors approached those of the general population, suggesting limited association between cancer and AD risk.
INTRODUCTION: Small observational studies with short-term follow-up suggest that cancerpatients are at reduced risk of Alzheimer's disease (AD) compared to the general population. METHODS: A nationwide cohort study using Danish population-based health registries (1980-2013) with cancerpatients (n = 949,309) to identify incident diagnoses of AD. We computed absolute reductions in risk attributed to cancer and standardized incidence rate ratios (SIRs) accounting for survival time, comparing the observed to expected number of AD cases. RESULTS: During up to 34 years of follow-up of cancer survivors, the attributable risk reduction was 1.3 per 10,000 person-years, SIR = 0.94 (95% confidence interval 0.92-0.96). SIRs were similar after stratification by sex, age, and cancer stage, and approached that of the general population for those surviving >10 years. DISCUSSION: Inverse associations between cancer and AD were small and diminished over time. Incidence rates in cancer survivors approached those of the general population, suggesting limited association between cancer and AD risk.
Authors: Rafael Tabarés-Seisdedos; Nancy Dumont; Anaïs Baudot; Jose M Valderas; Joan Climent; Alfonso Valencia; Benedicto Crespo-Facorro; Eduard Vieta; Manuel Gómez-Beneyto; Salvador Martínez; John L Rubenstein Journal: Lancet Oncol Date: 2011-04-15 Impact factor: 41.316
Authors: C M Roe; A L Fitzpatrick; C Xiong; W Sieh; L Kuller; J P Miller; M M Williams; R Kopan; M I Behrens; J C Morris Journal: Neurology Date: 2009-12-23 Impact factor: 9.910
Authors: Randall J Bateman; Chengjie Xiong; Tammie L S Benzinger; Anne M Fagan; Alison Goate; Nick C Fox; Daniel S Marcus; Nigel J Cairns; Xianyun Xie; Tyler M Blazey; David M Holtzman; Anna Santacruz; Virginia Buckles; Angela Oliver; Krista Moulder; Paul S Aisen; Bernardino Ghetti; William E Klunk; Eric McDade; Ralph N Martins; Colin L Masters; Richard Mayeux; John M Ringman; Martin N Rossor; Peter R Schofield; Reisa A Sperling; Stephen Salloway; John C Morris Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Jeremy D Baker; Lindsey B Shelton; Dali Zheng; Filippo Favretto; Bryce A Nordhues; April Darling; Leia E Sullivan; Zheying Sun; Parth K Solanki; Mackenzie D Martin; Amirthaa Suntharalingam; Jonathan J Sabbagh; Stefan Becker; Eckhard Mandelkow; Vladimir N Uversky; Markus Zweckstetter; Chad A Dickey; John Koren; Laura J Blair Journal: PLoS Biol Date: 2017-06-27 Impact factor: 8.029
Authors: Eleanor Hayes-Larson; Crystal Shaw; Sarah F Ackley; Scott C Zimmerman; M Maria Glymour; Rebecca E Graff; John S Witte; Lindsay C Kobayashi; Elizabeth Rose Mayeda Journal: J Gerontol A Biol Sci Med Sci Date: 2022-06-01 Impact factor: 6.591
Authors: Christoph Roderburg; Sven H Loosen; Anselm Kunstein; Raphael Mohr; Markus S Jördens; Mark Luedde; Karel Kostev; Tom Luedde Journal: Cancers (Basel) Date: 2021-04-22 Impact factor: 6.639
Authors: Monica Ospina-Romero; M Maria Glymour; Eleanor Hayes-Larson; Elizabeth Rose Mayeda; Rebecca E Graff; Willa D Brenowitz; Sarah F Ackley; John S Witte; Lindsay C Kobayashi Journal: JAMA Netw Open Date: 2020-11-02